Document:

EXHIBIT 10.12

*****Confidential  Treatment  has been requested for portions of this agreement.
The copy file herewith omits information subject to the confidentiality request.
Omissions are designated as [*****]. A complete version of  this  agreement  has
been filed separately with the Securities and Exchange Commission.

                               131 Park Street, NE
                           Vienna, Virginia 22180-4607
                              Phone: (703) 281-7440
                               FAX: (703) 281-7636

July 9, 1999                      LETTER AGREEMENT

InforMax
6010 Executive Blvd.
Suite 501
North Bethesda, MD 20852 USA

Attention:     Ms. Kimberly B. Durazo
               Director of Operations, InforMax, Inc.

Dear Mrs. Durazo,

In response  to the  proposal  provided  by  InforMax on July 2, 1999  regarding
contract  NO1-LM-5-3530  for the year  1999-2000,  the  following  agreement and
specified terms will supercede the prior sub-contract  arrangement  currently in
place. Each line item referenced below for this  fixed-priced  agreement will be
implemented  on  July  15,  1999.  Any  liabilities  from  the  prior  agreement
Subcontract No.: 1489-9601, will cease under this new agreement.

Contract is a FIRM-FIXED COST for one year, from July 15, 1999 to July 12, 2000.

The  following  labor  categories  and  rates  have  been  agreed  to by MSD and
InforMax:

One  Senior  Bio-Informatics  Software  Engineer  at an  annual  hourly  rate of
[*****].

Two Bio-Informatics Software Engineers at an annual hourly rate of [*****].

Three Bio-Informatics Software Engineers at an annual hourly rate of [*****].

Software  Engineer rates  increase with the start of the new contract  effective
July 15, 1999.

The total FIRM-FIXED cost for the one year contract will not exceed [*****].

MSD payments will be made to INFORMAX,  INC. within 30 days from date of receipt
for the period worked. An invoice will be submitted by INFORMAX to MSD via email
on the first of every month.  MSD and INFORMAX will meet on a quarterly basis to
ensure that hours and billings are maintained to satisfy the terms  specified in
the agreement.

INFORMAX will provide monthly to MSD, copies of signed  employee  timesheets,  a
summary  report of actual hours worked to date by each  employee and an employee
job status report.  This  agreement is for [*****] hours in accordance  with the
rates above for a fixed price annual total of [*****].

<PAGE>

Please execute two signed  originals of this agreement.  MSD will then sign both
and return one original for your files. MSD looks forward to continuing  or long
standing  partnership  with  InforMax with this  agreement.  Please feel free to
contact  myself  or Jim Fox (703)  281-7440  x124  regarding  any  questions  or
clarifications to this agreement.

Very truly yours,

Haley Esser
MSD Program Manager

/s/ James A. Fox                                   7/12/99
------------------                                 ---------
James A Fox                                         Date
MSD, Vice President

/s/ Joseph Lehnen                                  7/9/99
-------------------                                ---------
Joseph Lehnen                                       Date
INFORMAX, Chief Financial Officer

<PAGE>

*****Certain information on this page has been omitted and filed separately with
the  Securities  and  Exchange   Commission.   Confidential  Treatment  has been
requested with respect to the omitted portions.

November 22, 1999

InforMax
6010 Executive Blvd. 10th Floor
Suite 501
North Bethesda, MD 20852 USA

Attention:     Ms. Kimberly B. Durazo
               Director of Operations, InforMax, Inc.

Dear Mrs. Durazo,

This  addendem is submitted  in support of the proposal  provided by InforMax on
July 2,  1999  regarding  contract  NO1-LM-5-3530  for the year  1999-2000.  The
following  agreement  and  specified  terms are subject to the Letter  Agreement
referenced above.

Contract is a FIRM-FIXED  COST for one year,  from  November 8, 1999 to November
5th, 2000.

One  Senior  Bio-Informatics  Software  Engineer  at an  annual  hourly  rate of
[*****].

The total FIRM-FIXED cost for the one-year contract will not exceed [*****].

MSD payments will be made to INFORMAX,  INC. within 30 days from date of receipt
for the period worked. An invoice will be submitted by INFORMAX to MSD via email
on the first of every  month.  THIS  INVOICE  SHALL  REFERENCE  MSD ORDER NUMBER
#1986.  MSD and INFORMAX will meet on a quarterly basis to ensure that hours and
billings are maintained to satisfy the terms specified in the agreement.

INFORMAX will provide monthly to MSD, copies of signed  employee  timesheets,  a
summary  report of actual hours worked to date by each  employee and an employee
job status report.  This  agreement is for [*****] hours in accordance  with the
rates above for a fixed price annual total of [*****].

Please feel free to contact  myself or Jim Fox (703) 281-7440 x124 regarding any
changes or clarifications to this agreement.

Very truly yours,

/s/ Haley Esser

Haley Esser
MSD Program Manager

<PAGE>

James A. Fox                                       11/22/99
------------------                                 ---------
James A Fox                                         Date
MSD, Vice President

Joseph Lehnen                                      11/29/99
-------------------                                --------
Joseph Lehnen                                       Date
INFORMAX, Chief Financial Officer

<PAGE>

[GRAPHIC OMITTED]

*****Certain information on this page has been omitted and filed separately with
the  Securities  and  Exchange   Commission.   Confidential  Treatment  has been
requested with respect to the omitted portions.

November 22, 1999

InforMax
6010 Executive Blvd. 10th Floor
North Bethesda, MD 20852 USA

Attention:   Ms. Kimberly B. Durazo
             Director of Operations, InforMax, Inc.

Dear Ms. Durazo,

This  addendum is submitted  in support of the proposal  provided to InforMax on
July 9,  1999  regarding  contract  NO1-LM-5-3530  for the year  1999-2000.  The
following  agreement  and  specified  terms are subject to the Letter  Agreement
referenced above.

Contract is a FIRM-FIXED COST for one year, from September 20, 1999 to September
17, 2000.

One  Senior  Bio-Informatics  Software  Engineer  at an  annual  hourly  rate of
[*****].

The total FIRM-FIXED cost for the one-year contract will not exceed [*****].

MSD  payments  will be made to  INFORMAX,  INC.  within 30 days from the date of
receipt for the period  worked.  An invoice will be submitted by INFORMAX to MSD
via email on the first of every month.  This invoice  shall  reference MSD order
number  #2029.  MSD and INFORMAX  will meet on a quarterly  basis to ensure that
hours  and  billings  are  maintained  to  satisfy  the terms  specified  in the
agreement.

INFORMAX will provide monthly to MSD, copies of signed  employee  timesheets,  a
summary  report of actual hours worked to date by each  employee and an employee
job status report.  This  agreement is for [*****] hours in accordance  with the
rates above for a fixed price annual total of [*****].

Please feel free to contact  myself or Jim Fox (703) 281-7440 x124 regarding any
changes or clarifications to this agreement.

Very truly yours,

/s/ Haley Esser

Haley Esser
MSD Program Manager
<PAGE>

Addendum #1

/s/ James A. Fox                        11/22/99
---------------------------------       --------
MSD, Vice President                     Date

/s/ Joseph Lehnen                       11/27/99
---------------------------------       --------
INFORMAX, Chief Financial Officer       Date

<PAGE>

     Certain information on this page has been omitted and filed separately with
the  Securities  and  Exchange  Commission.   Confidential  treatment  has  been
requested with respect to the omitted portions.

                                  PURCHASE ORDER                       Order No.
                                                                            2385
                              PHONE (703) 281-7440

                                       ITG

To:       Informax                  Ship To:  Management Systems Designers, Inc.
Address:  6010 Executive Blvd.      Address:  131 Park Street, N.E.
City:     North Bethesda, MD        City:     Vienna, Virginia
          20852                               22180

ACCT.            Date Required    Terms      How Ship     Date     7.26.00

                 The following categories (labor) and rates
                 Have been agreed to by MSD and Informax:

                 - [****] : [****] Hrs. @ [****] =           [****]
                 - [****] : [****] Hrs. @ [****] =           [****]
                 - [****] : [****] Hrs. @ [****] =           [****]
                 - [****] : [****] Hrs. @ [****] =           [****]
                 - [****] : [****] Hrs. @ [****] =           [****]
                 - [****] : [****] Hrs. @ [****] =           [****]

                 MSD Payments will be made to Informax, Inc.
                 Within 30 days from the date of receipt for
                 The period worked.  An invoice will be submitted
                 By Informax to MSD via e0mail on the first
                 Of every month.

                 Informax will provided monthly to MSD, copies
                 Of signed employee timesheets, a summary
                 Report of actual hours worked to date by each
                 Employee and an employee job status report.

                                                    TOTAL:   [****]

                 Period of performance: August 6, 2000-
                                        August 5, 2001

Our order number appear on all                       /s/ Illegible
invoices, packages, etc.

Please notify us immediately if you are
unable to ship complete order by date
specified
White-original                Yellow-Office Copy                  Pink-Receiving

<PAGE>

     Certain information on this page has been omitted and filed separately with
the  Securities  and  Exchange  Commission.   Confidential  treatment  has  been
requested with respect to the omitted portions.

                                  PURCHASE ORDER                       Order No.
                                                                            2461
                              PHONE (703) 281-7440

                                       ITG

To:       Informax                  Ship To:  Management Systems Designers, Inc.
Address:  6010 Executive Blvd.      Address:  131 Park Street, N.E.
City:     North Bethesda, MD        City:     Vienna, Virginia
          20852                               22180

ACCT.            Date Required    Terms      How Ship     Date

                 Consulting services for:

                   [****] at $ [****] Per Hr. for [****] hours
                 Period of performance: September 18, 2000-
                                        September 17, 2001
                   [****] at $ [****] Per Hr. for [****] hours

                        Contract Type: Time & Materials

                                                      1518-001-46
                                                      -------------------
Our order number appear on all                        /s/ Illegible
invoices, packages, etc.

Please notify us immediately if you are
unable to ship complete order by date
specified

White-original                Yellow-Office Copy                  Pink-ReceivingEXHIBIT 10.19

***** Confidential  Treatment  has been requested for portion of this agreement.
The copy file herewith omits information subject to the confidentiality request.
Omissions are designated as [*****]. A complete version of  this  agreement  has
been filed separately with the Securities and Exchange Commission.

                       DATA ANALYSIS PRODUCTS DEVELOPMENT
                           AND DISTRIBUTION AGREEMENT

     This  Data  Analysis  Products   Development  and  Distribution   Agreement
("Agreement")  is made this 16th day of August,  2000 (the "Effective  Date") by
and between Amersham  Pharmacia  Biotech Inc., a Delaware  corporation,  with an
office at 800  Centennial  Avenue,  Piscataway,  New Jersey  08855  ("APB")  and
InforMax,  Inc.,  a  Delaware  corporation,  with an  office  at 6010  Executive
Boulevard,  Rockville, Maryland 20852 ("InforMax").  APB and InforMax shall each
individually be referred to as "Party" and collectively as the "Parties."

SECTION 1 - DEFINITIONS

     The  following  terms and any other terms defined in this  Agreement  shall
have the meaning associated therewith, whether such term is used in the singular
or plural form.

     1.1  BIOTECH  MARKET.  "Biotech  Market"  shall mean any life  sciences  or
biotechnology  company  whose  principal  place of  business is located in North
America  or  Western  Europe  that is not  ranked  among the top fifty (50) life
sciences  and  biotechnology  companies as ranked by revenues at the end of each
calendar year. The parties shall mutually agree upon a source that publishes the
revenue  rankings of life sciences and  biotechnology  companies for purposes of
this Section 1.1.

     1.2 BUSINESS INFORMATION AGREEMENT.  "Business Information Agreement" shall
mean the agreement  between APB and InforMax for the  development and license of
the Espresso platform and any other platform the Parties agree upon.

     1.3  DATA  ANALYSIS  PRODUCTS.  "Data  Analysis  Products"  shall  mean the
software  products  developed by InforMax  substantially  in accordance with the
Specifications,  and  acceptance  test  criteria set forth in Exhibit A attached
hereto and  incorporated  herein by  reference.  The  functionality  of the Data
Analysis Products shall include,  but not be limited to, the following:  [*****]
The Data  Analysis  Products  will  consist of the  Jointly  Developed  Code (as
defined below) combined with the InforMax Software.

     1.4 END USERS.  "End Users"  shall mean the  external end users of the Data
Analysis Products.

              EXECUTION COPY - DATA ANALYSIS PRODUCTS DEVELOPMENT
                      AND DISTRIBUTION AGREEMENT - PAGE 1

<PAGE>

     1.5  INFORMAX  SOFTWARE.   "InforMax  Software"  shall  mean  the  software
identified on Exhibit B attached hereto and incorporated by reference.

     1.6  JOINTLY  DEVELOPED  CODE.  "Jointly  Developed  Code"  shall  mean the
computer code created by InforMax pursuant to Exhibit A.

     1.7 LIFE SCIENCES  MARKET.  "Life Sciences  Market" shall mean (i) any life
sciences or  biotechnology  company whose principal place of business is located
in North  America  or  Western  Europe  and is ranked in the top fifty (50) life
sciences  and  biotechnology  companies as ranked by revenues at the end of each
calendar  year,  and (ii) any  life  sciences  or  biotechnology  company  whose
principal  place of  business  is located  outside of North  America and Western
Europe.  The  parties  shall  mutually  agree upon a source that  publishes  the
revenue  rankings of life sciences and  biotechnology  companies for purposes of
this Section 1.7.

     1.8 MAINTENANCE.  "Maintenance" shall mean those services provided pursuant
to Sections 5.4, 5.5, 5.6 and 5.7.

     1.9 MAINTENANCE FEES. "Maintenance Fees" shall mean the fees paid by an End
User for all Maintenance.

     1.10 NORTH  AMERICA.  "North  America"  shall  mean the  United  States and
Canada.

     1.11 SPECIFICATIONS. "Specifications" shall mean the technical requirements
for the Data Analysis Products set forth in Exhibit A.

     1.12 SUBSIDIARY.  A "Subsidiary"  shall mean any corporation or entity that
is owned or controlled by APB and/or its parent corporation. Except as set forth
in Section  3.1(a),  to be owned means that at least twenty percent (20%) of all
equity  interests  in  the  subsidiary  corporation  or  subsidiary  entity  are
beneficially owned by APB and/or its parent corporation.  To be controlled means
that APB and/or its parent has the right and authority to appoint and direct the
management of the Subsidiary corporation or Subsidiary entity.

     1.13  WESTERN  EUROPE.  "Western  Europe"  shall mean the  United  Kingdom,
Ireland, France, Germany, Spain, Portugal, Italy, Switzerland,  Austria, Sweden,
Finland, Norway, Denmark, The Netherlands,  Belgium, Greece, Iceland,  Luxemberg
and Liechtenstein.

SECTION 2 - DEVELOPMENT AND DELIVERY

     2.1 DEVELOPMENT OF DATA ANALYSIS PRODUCTS.  InforMax shall use commercially
reasonable  efforts to develop the Data Analysis Products in accordance with the
Specifications.  The development of the Data Analysis  Products will include the
development of the Jointly  Developed Code combined with the InforMax  Software.
In the event  that  InforMax  does not use  commercially  reasonable  efforts to
develop the Data Analysis  Products,  APB shall have the right to terminate this
Agreement  immediately without penalty to InforMax and shall also have the right
to seek all available legal and equitable remedies.

              EXECUTION COPY - DATA ANALYSIS PRODUCTS DEVELOPMENT
                      AND DISTRIBUTION AGREEMENT - PAGE 2

<PAGE>

     2.2 SPECIFICATIONS DEVELOPMENT. The Parties hereby acknowledge that Exhibit
A attached hereto is not in final form.  Upon execution of this  Agreement,  the
Parties shall use commercially  reasonable  efforts to complete Exhibit A within
one hundred eighty (180) days  following the Effective  Date. The parties hereby
agree that Exhibit A shall include the  Specifications,  schedules,  milestones,
completion dates and acceptance testing criteria applicable to the Data Analysis
Products.

     2.3 PROCESS DEVELOPMENT. Simultaneously with the preparation and completion
of Exhibit A, the Parties shall use commercially reasonable efforts to establish
mutually  agreed upon  procedures  and guidelines  for the  development  process
within one hundred eighty (180) days following the Effective Date.

     2.4   DOCUMENTATION.   The  Data   Analysis   Products  will  include  that
documentation  developed by InforMax for use by End Users with the Data Analysis
Products.   Such   documentation   shall  hereinafter  be  referred  to  as  the
"Documentation."  All  references in this  Agreement to Data  Analysis  Products
shall also apply to the Documentation to the extent that the context  reasonably
permits.

     2.5 DELIVERY. Within thirty (30) days of the Effective Date, InforMax shall
deliver to APB the currently  existing  development  platform  documentation  as
described on Exhibit A attached hereto,  and within one hundred and eighty (180)
days thereafter the Parties shall identify all modifications to such development
platform documentation, and all additional platform documentation, which must be
provided to APB on such  milestone  dates as the Parties  shall  mutually  agree
within the same hundred and eighty (180) days.  In any event,  upon a request by
APB any time after December 31, 2001, InforMax shall promptly deliver to APB all
available   development   platform   documentation.   After  completion  of  the
development of the Data Analysis Products,  InforMax shall deliver copies of the
Data Analysis Products, including the source code to the Jointly Developed Code,
to APB for acceptance testing pursuant to Section 4.

     2.6 OWNERSHIP.

         (a) DATA ANALYSIS PRODUCTS AND JOINTLY DEVELOPED CODE. InforMax and APB
shall  jointly own all right,  title and  interest  in and to the Data  Analysis
Products and the Jointly  Developed Code, and all  intellectual  property rights
associated therewith, including but not limited to patents, copyrights, know-how
and trade  secrets,  and each Party shall take all steps  necessary  to vest and
perfect such title in the other, regardless of whether any work or invention was
authored or developed solely by one party hereunder. Each Party's right, if any,
to license,  distribute,  use, copy and modify the Data Analysis Products and to
any  compensation  as a result  of the  other  Party's  transfer,  sale or other
exploitation of the Data Analysis  Products,  shall be determined solely by this
Agreement.  InforMax agrees that it shall use the Data Analysis Products and any
rights thereto solely for the purposes of carrying out this Agreement, provided,
however,  that subject to Section 5.9,  nothing herein shall limit or in any way
restrict  InforMax's  right,  title or use of  InforMax  Software  or any  other
know-how  arising out of this  Agreement  or any  intellectual  property  rights
therein.

              EXECUTION COPY - DATA ANALYSIS PRODUCTS DEVELOPMENT
                      AND DISTRIBUTION AGREEMENT - PAGE 3

<PAGE>

         (b) INFORMAX  SOFTWARE.  APB agrees and acknowledges  that InforMax and
its suppliers are, and shall remain, the owners of all right, title and interest
in and to the InforMax Software,  including all documentation,  enhancements and
updates thereto and all intellectual  property rights therein,  and that APB and
its Subsidiaries and its Resellers (as defined below) shall not obtain or claim,
pursuant  to this  Agreement  or its rights  granted  hereunder,  any  ownership
interest in the InforMax Software or any documentation,  enhancements or updates
thereto, or any intellectual property rights therein.

         (c) APB SOFTWARE.  InforMax  acknowledges that APB may, during the term
of this Agreement provide InforMax with certain APB proprietary software. In the
event that APB does provide InforMax with any APB proprietary software, InforMax
acknowledges that APB shall remain the owner of all right, title and interest in
and to such APB proprietary software, including all documentation,  enhancements
and updates thereto and all intellectual  property rights therein,  and InforMax
shall not claim any ownership interest in such APB proprietary software.

SECTION 3 - USE, DISTRIBUTION AND SUBLICENSING OF DATA ANALYSIS PRODUCTS

     3.1 LICENSE GRANTS.

         (a)  INTERNAL  USE  LICENSE.  InforMax  hereby  grants  to APB  and its
Subsidiaries  during the term of this  Agreement  a  world-wide,  royalty  free,
transferable  (only to the extent  permitted by Section 13.3 herein)  license to
use InforMax's  GenoMax  software as part of the Data Analysis  Products at such
sites  and   facilities   owned  or  controlled  by  APB  or  its   Subsidiaries
(hereinafter, the "Internal Use License"). InforMax shall provide Maintenance to
APB at no  cost  in  connection  with  the  Internal  Use  License  pursuant  to
InforMax's then-current Maintenance plan. The Internal Use License is restricted
to internal use by APB and its Subsidiaries.  APB and its Subsidiaries  shall be
permitted to make a limited number of copies of the InforMax GenoMax software as
reasonably  necessary  to exercise  the  Internal Use License and for back-up or
archival purposes. For purposes of this Section 3.1(a) only,  "Subsidiary" shall
mean an entity of which  APB owns  greater  than a fifty  percent  (50%)  equity
interest.

         (b) APB DISTRIBUTION  LICENSE.  Subject to the terms and conditions set
forth in this Agreement,  InforMax hereby grants APB and its Subsidiaries during
the term of this Agreement,  a world-wide  exclusive,  transferable (only to the
extent permitted by Section 13.3 herein) right and license to (i) distribute and
sublicense,  directly or indirectly  through Resellers (as defined below) to End
Users,  the  InforMax  Software  solely in bundled  form with the Data  Analysis
Products; (ii) to demonstrate,  market, advertise and promote to prospective End
Users the  InforMax  Software  solely  in  bundled  form with the Data  Analysis
Products;  and (iii)  make a  reasonable  number of copies of the Data  Analysis
Products  and use such  copies in  accordance  with the terms set forth  herein.
"Resellers" shall mean any distributors, dealers and retailers of APB.

         (c)  INFORMAX  TRADEMARK  LICENSE.   Subject  to  InforMax's   standard
trade-mark usage  guidelines,  which InforMax may amend from time to time in its
sole discretion,

              EXECUTION COPY - DATA ANALYSIS PRODUCTS DEVELOPMENT
                      AND DISTRIBUTION AGREEMENT - PAGE 4

<PAGE>

InforMax  hereby  grants to APB the  right to use and  display  the  trademarks,
tradenames,  service marks and logos set forth on Exhibit C attached  hereto and
incorporated  herein by  reference  (the  "Marks"),  solely in  connection  with
discharging  its  rights  and  obligations  under  this  Agreement.  APB and its
Subsidiaries  and  Resellers  shall  be  obligated  to  use  the  Marks  in  its
performance   hereunder,   including  but  not  limited  to,  its   distribution
obligations set forth in 3.1(b) above.  APB and its  Subsidiaries  and Resellers
shall  not use the  Marks,  or any other  trademarks,  service  marks,  logos or
tradenames  of  InforMax,  or any word,  symbol or  design  confusingly  similar
thereto, as part of its corporate name, or as part of the name of any product of
APB or it Subsidiaries.

         (d) APB TRADEMARK LICENSE. To the extent necessary and subject to APB's
standard trademark usage guidelines which APB may amend from time to time in its
sole  discretion,  and once the parties  have  agreed upon a marketing  plan and
budget pursuant to Section 5.8(a),  APB shall grant to InforMax the right to use
and display such trademarks, tradenames, service marks and logos of APB that are
reasonably  necessary in connection with  discharging its rights and obligations
under this Agreement. InforMax shall not use any trademarks, tradenames, service
marks and  logos of APB,  or any word,  symbol  or  design  confusingly  similar
thereto, as part of its corporate name, or as part of the name of any product of
InforMax or its subsidiaries.

     3.2  RESTRICTIONS.  The  rights  and  licenses  granted  to APB and its
Subsidiaries and Resellers in Section 3.1 above shall be limited as follows:

         (a) APB and/or its  Subsidiaries and Resellers may not in any way sell,
lease, rent, license,  sublicense or otherwise  distribute the InforMax Software
or the Data  Analysis  Products,  or any part  thereof,  to any person or entity
except in bundled form as the Data Analysis Products.

         (b) APB and/or its  Subsidiaries  and  Resellers  shall not re-brand or
private label the InforMax Software.

         (c) APB and/or its  Subsidiaries  and Resellers shall not  disassemble,
decompile or  otherwise  reverse  engineer  the  InforMax  Software or otherwise
attempt to learn the source code, structure,  algorithms or ideas underlying the
InforMax Software or knowingly allow any third parties to do so.

     3.3 COPYING AND  PRODUCTION.  InforMax shall provide five (5) master copies
of the Data  Analysis  Products to APB.  APB will use the master  copies to make
copies  of  the  Data   Analysis   Products  as  permitted   for   distribution,
demonstration,  advertising, and marketing pursuant to this Agreement. APB shall
also have the right to make a reasonable  number of copies of the Data  Analysis
Products  for  back-up  and  archival  purposes.  APB  shall  bear all  costs of
production, distribution, media, printing, and packaging.

     3.4 END USER LICENSE  AGREEMENT.  APB acknowledges and agrees that APB must
grant each End User a license to use the Data  Analysis  Products  and that each
End User must execute a written end user license  agreement  with APB to use the
Data Analysis Products (the

              EXECUTION COPY - DATA ANALYSIS PRODUCTS DEVELOPMENT
                      AND DISTRIBUTION AGREEMENT - PAGE 5

<PAGE>

"End User License Agreement"). The End User License Agreement will be consistent
with the terms and  conditions of this Agreement and will include such terms and
conditions as are customary for the protection of similar software  products and
shall include all necessary terms and conditions reasonably required by InforMax
to adhere to its revenue recognition policies and procedures.  In addition,  the
End User  License  Agreement  shall state that (i)  InforMax is the owner of the
InforMax Software;  (ii) InforMax is the co-owner of the Data Analysis Products;
and (iii)  InforMax  is a third  party  beneficiary  under the End User  License
Agreement and that InforMax shall have the right to enforce the End User License
Agreement to the extent  necessary  or  appropriate  to protect its  proprietary
rights in the  InforMax  Software  and the Data  Analysis  Products.  APB hereby
covenants that the obligations set forth in this Section 3.4 shall also apply to
Resellers  and that APB shall  require all Resellers to comply with this Section
3.4.

SECTION 4 - ACCEPTANCE

     4.1 ACCEPTANCE PERIOD. APB may test each Data Analysis Product for a thirty
(30) day  period  beginning  on the date of receipt  by APB from  InforMax  (the
"Acceptance Period"). APB may reject each delivered Data Analysis Product within
the  Acceptance  Period  due to the  failure  of such Data  Analysis  Product to
materially  perform in  accordance  with the  acceptance  criteria  set forth in
Exhibit A.  Acceptance of each  delivered Data Analysis  Product  ("Acceptance")
will be effective on the earliest to occur of the  following:  (1)  provision by
APB of a notice of  acceptance,  or (2)  failure of APB to accept or reject each
delivered Data Analysis Product within the Acceptance Period.

     4.2 REJECTION.  If any Data Analysis Product is rejected by APB pursuant to
Section 4.1,  InforMax will have thirty (30) days from receipt of such notice of
rejection  to  correct  any  non-conformities  and  APB  will  then  have  a new
acceptance  period of thirty (30) days from the receipt of the corrected copy of
such Data  Analysis  Product  to test such  corrected  copy in  accordance  with
Section 4.1 above. In the event that APB rejects any Data Analysis  Product more
than three (3) times, a representative  from the senior management of each Party
shall meet and attempt to devise a mutual  resolution  regarding any outstanding
non-conformities  within five (5) days after the third  rejection.  In the event
such  senior  managers  are unable to resolve any  outstanding  non-conformities
within ten (10) days after such  meeting,  this  Agreement  may be terminated by
either Party  without  penalty to the other  Party.  InforMax  acknowledges  and
agrees that in the event of termination  pursuant to this Section 4.2, APB shall
have  the  right  to  pursue  any  remedies  it may  have in law or  equity  for
InforMax's  failure to use commercially  reasonable  efforts to develop any Data
Analysis  Product;  APB acknowledges and agrees that in the event of termination
pursuant  to this  Section  4.2,  InforMax  shall  have the right to pursue  any
remedies it may have in law or equity if APB rejects any Data  Analysis  Product
on grounds other than those permitted by this Agreement.

SECTION 5 - END USER SERVICES/DISTRIBUTION EFFORTS

     5.1 TRAINING OF APB REPRESENTATIVES.

         (a) INITIAL TRAINING.  InforMax will provide,  at no additional charge,
initial  training to APB which  shall  consist of  training  including,  but not
limited to, the use and

              EXECUTION COPY - DATA ANALYSIS PRODUCTS DEVELOPMENT
                      AND DISTRIBUTION AGREEMENT - PAGE 6

<PAGE>

troubleshooting  of the Data Analysis  Products.  Such initial training shall be
conducted  in  Sunnyvale  (California,  USA),  Cardiff  (Wales,  UK) and Uppsala
(Sweden)  and  shall  take  place  over a period  of up to two (2) weeks at each
location.  The initial  training  may be  attended by a combined  total of up to
sixty (60) employees of APB.

         (b)  PLACEMENT.  At APB's  request,  InforMax  will place up to two (2)
InforMax employee  programmers from InforMax's research and development group of
an  appropriate  skill level and who are  reasonably  acceptable to APB at APB's
Sunnyvale site for up to four (4) months.  Such employees  shall not include any
member of InforMax' field and/or technical  support group located in California.
Such employees may also provide  services to APB under the Business  Information
Agreement.  For  avoidance  of doubt,  InforMax  will only have to place two (2)
employees total under both this Agreement and the Business Information Agreement
at the APB site in California.

     5.2 PROJECT  COMMITTEE.  APB and InforMax  will form a "Project  Committee"
comprised of one (1) senior  manager from each Party's  technical  support team.
Commencing upon execution of this Agreement,  the Project Committee will meet on
a monthly basis,  either in person at a site to be agreed upon by the Parties or
via  teleconference,  for the primary purpose of ensuring timely  development of
the Data Analysis Products and coordinating the End User services.  On an annual
basis,  the APB Project  Committee  member will  provide  the  InforMax  Project
Committee  member a proposed draft of the development plan and the products that
it proposes to be developed  during the upcoming  year.  The Parties  shall then
mutually  agree upon a final  draft of such  development  plan,  which shall set
forth the obligations of each Party for such development.

     5.3 CUSTOMER  CONTRACTS;  END USER  MAINTENANCE.  The contractual  customer
relationships  related to the Data Analysis Products and the Maintenance thereto
shall be between APB and the End User.  APB will  provide  InforMax the relevant
information  for each End User  (e.g.,  End User  name,  address,  and  types of
service  requested).  The following services will be made available to End Users
at InforMax's then-current rates with no royalty obligations to APB:

         (a) INSTALLATION,  IMPLEMENTATION AND INTEGRATION.  InforMax,  at APB's
request, will provide  installation,  implementation and integration of the Data
Analysis Products for the End User.

         (B) TRAINING OF END USERS.  InforMax,  at APB's  request,  will provide
reasonable training to End Users regarding the use and functionality of the Data
Analysis Products.

         (C) OTHER  SERVICES.  The End User may  request  APB to  perform  other
professional  services  regarding the Data Analysis  Products.  In the event APB
does not perform such  services,  it will give InforMax a right of first refusal
to perform such services.

              EXECUTION COPY - DATA ANALYSIS PRODUCTS DEVELOPMENT
                      AND DISTRIBUTION AGREEMENT - PAGE 7

<PAGE>

     5.4 BACK-UP TECHNICAL SUPPORT.

         (a) SUPPORT  OBLIGATIONS.  Each Party will provide  support as follows:
(i) APB will provide End Users first line  technical  phone support for the Data
Analysis  Products and such telephone support will be available during the hours
of 9 a.m. to 5 p.m.  (Eastern  Standard  Time) from Monday to Friday,  excluding
APB's company  holidays;  and (ii)  InforMax  shall  provide  back-up  technical
support  to APB  with  respect  to the  Data  Analysis  Products.  This  back-up
technical  support  will be  available  during  the  hours  of 9 a.m.  to 5 p.m.
(Eastern  Standard  Time) from Monday to Friday,  excluding  InforMax's  company
holidays.  The  back-up  technical  support  will  be  provided  to APB  through
telephone,  e-mail  and  other  appropriate  means  of  communication.   Back-up
technical  support also  includes  those  services  set forth in Section  5.4(b)
below.

         (b) ERRORS.  An "Error" means a programming error or defect in the Data
Analysis  Products  that causes the Data  Analysis  Products to  malfunction  or
produce  erroneous  results.  A "Critical  Error"  means an Error that,  despite
implementation of work-around  solutions,  if any, provided by InforMax,  causes
the Data Analysis  Products to crash or that otherwise  adversely affects an End
User to the extent  that the Data  Analysis  Products  is not useable by the End
User. A  "non-Critical  Error" is any Error other than a Critical  Error. In the
event that a Critical  Error is  reported  by APB to  InforMax,  InforMax  shall
respond to APB regarding the Critical Error as follows:

             (i)    Within one (1) business  day,  InforMax  will respond to the
call or other communication reporting the Critical Error and an InforMax support
person  will be  assigned to  diagnosis  or  troubleshoot  the  Critical  Error.
Diagnosis or troubleshooting will begin at this time.

             (ii)   Within three (3) business days, an InforMax programmer  will
begin creating a patch,  fix or other  correction to address the Critical Error.
However, if the diagnosis or troubleshooting  has not yet adequately  identified
and revealed the nature of the Critical  Error,  InforMax may delay the creation
of a patch, fix or other correction as necessary,  provided that InforMax remain
diligent in the diagnosis and troubleshooting of the Critical Error.

             (iii)  InforMax may provide temporary  work-around  solutions prior
to providing a permanent  patch, fix or correction.  If a temporary  work-around
solution causes a Critical Error to become a non-Critical  Error, then the Error
shall thereafter be governed as a non-Critical Error.

             (iv)   If a visit to an End User  site is  reasonably  required  to
diagnose  or  troubleshoot  the  Critical  Error or for a patch,  fix,  or other
correction to the Critical Error,  then InforMax shall send support personnel to
the End User site.

Non-Critical  Errors  shall be  addressed  by InforMax  in the normal  course of
maintenance as provided under Section 5.5 below.

     5.5 ERROR CORRECTION. InforMax shall provide Error Corrections for the Data
Analysis Products.  "Error  Corrections" shall consist of: (a) the correction of
Errors that cause the Data Analysis Products to malfunction or produce erroneous
results,  and/or (b) the provision of

              EXECUTION COPY - DATA ANALYSIS PRODUCTS DEVELOPMENT
                      AND DISTRIBUTION AGREEMENT - PAGE 8

<PAGE>

reasonable  work-around  solutions for such Errors.  Error  Correction  does not
include any right to new or different features or functionality.

     5.6 UPDATES. InforMax will provide to End Users updates, fixes or revisions
pursuant to Section 5.5 for use with the Data Analysis Products ("Updates"). Any
Updates shall be governed by this  Agreement as Data  Analysis  Products and all
references  in this  Agreement  to Data  Analysis  Products  will  include  such
Updates.

     5.7 UPGRADES. If and when InforMax upgrades the InforMax Software, InforMax
will upgrade the Data  Analysis  Products as necessary by replacing the outdated
InforMax  Software  in the Data  Analysis  Products  with the new version of the
InforMax   Software  and  by  making  such  changes  and   enhancements  to  and
replacements of the Jointly  Developed Code ("Upgraded  Jointly Developed Code")
as are necessary to make the Jointly  Developed Code  compatible and useful with
the new version of the InforMax  Software.  An upgrade to the InforMax  Software
means a new  version of the  InforMax  Software  which is  characterized  by new
features or  functionality  or other  improvements  and which is  designated  by
InforMax  with a new version  number (a new version will be software  that has a
numerical  change on the left side of the decimal of the version  number  (e.g.,
version  1.0 to version  2.0)).  The  corresponding  upgrades  to Data  Analysis
Products are referred to as  "Upgrades."  Any Upgrades shall be governed by this
Agreement as Data Analysis Products and all references in this Agreement to Data
Analysis  Products will include such Upgrades.  All references in this Agreement
to InforMax Software will include such upgraded InforMax Software.  Any Upgraded
Jointly  Developed Code shall be governed by this Agreement as Jointly Developed
Code and all references in this Agreement to Jointly Developed Code will include
such Upgraded Jointly Developed Code.

     5.8 DISTRIBUTION OBLIGATIONS FOR THE DATA ANALYSIS PRODUCTS.

         (a) APB MARKETING  BUDGET.  Within one hundred eighty (180) days of the
Effective Date, and on an annual basis each year  thereafter,  the Parties shall
mutually  agree  upon  a  marketing  plan  and  budget  that  sets  forth  APB's
anticipated  marketing  obligations and the amount of funds it shall dedicate to
its  performance  hereunder for each upcoming year.  APB shall use  commercially
reasonable  efforts to  implement  such  marketing  plan and budget on an annual
basis.  In the event that APB does not use  commercially  reasonable  efforts to
implement the marketing and budget plan in any given year,  InforMax  shall have
the right to terminate this Agreement  immediately  without  penalty to APB, its
Subsidiaries  or Resellers  and shall also have the right to seek all  available
legal and equitable remedies.

         (b) MARKETING  COMMITTEE.  APB and InforMax will also form a "Marketing
Committee"  comprised  of one (1) senior  manager  from each  Party's  sales and
marketing  team.  Commencing at least two (2) months prior to launch date of the
first Data  Analysis  Product,  the Marketing  Committee  will meet on a monthly
basis,  whether  in  person at a site to be agreed  upon by the  Parties  or via
teleconference,  for the  primary  purpose  of  discussing  marketing  and sales
channel strategies.  The parties shall also agree on how each respective Party's
sales organization shall staff End User accounts and all potential new accounts,
and the  procedure  for APB to register and qualify  prospects.  For purposes of
Section  6.2(b) and 6.3(b) APB shall have  registered  a prospect if APB makes a
formal  presentation  to a prospective End User regarding a

              EXECUTION COPY - DATA ANALYSIS PRODUCTS DEVELOPMENT
                      AND DISTRIBUTION AGREEMENT - PAGE 9
<PAGE>

license for the Data  Analysis  Products.  InforMax  hereby  agrees that it will
provide to APB all assistance  reasonably necessary for APB and its Subsidiaries
and Resellers to market and promote the Data Analysis  Products  including,  but
not  limited  to,  assisting  APB  with  lead  generation,   presentations   and
demonstrations.

     5.9  NON-SOLICITATION.  The  Parties  hereby  agree that once either of the
Parties  has made an  initial  formal  presentation  to a  prospective  End User
regarding the licensing of the Data Analysis Products,  each Party shall refrain
from  offering to such  prospective  End User its own products and services on a
stand-alone basis until the earlier of: (i) the date upon which such prospective
End User notifies  either Party that it is not  interested in licensing the Data
Analysis  Products,  or (ii) six (6) months from the date that either Party made
such initial formal presentation to such prospective End User regarding the Data
Analysis Products.

SECTION 6 - PAYMENTS

     6.1  LICENSE  FEES.  During  the term of this  Agreement,  APB shall pay to
InforMax the non-refundable license fees and Maintenance Fees in accordance with
the amounts set forth in  Sections  6.2 and 6.3 below and  pursuant to the other
terms and  conditions set forth in this Section 6. All payments owed to InforMax
by APB  shall  be made  within  fifteen  (15)  days  after  the last day of each
calendar  quarter  in  which  the End  User has  executed  the End User  License
Agreement,  provided, however, that if an End User breaches the End User License
Agreement and does not pay APB, APB shall not be obligated to pay InforMax.  For
purposes of this Section 6, "net license  fees and  Maintenance  Fees" means the
license  fees and  Maintenance  Fees  owed by an End User for the Data  Analysis
Products excluding taxes and freight.

     6.2 LIFE SCIENCES MARKET.

         (a) For every license to the Data Analysis Products granted by APB, its
Subsidiaries and Resellers to End Users in the Life Sciences  Market,  APB shall
pay InforMax  sixty percent (60%) of the net license fees and  Maintenance  Fees
(to be paid at the time of the license grant) owed by each End User for the Data
Analysis Products pursuant to such transaction.

         (b) In the event that an End User in the Life Sciences  Market  decides
not to  license  the Data  Analysis  Products,  but does  license  the  InforMax
Software on a standalone basis directly from InforMax,  InforMax shall pay APB a
fifteen  percent  (15%)  of the net  license  fee  paid  to  InforMax  for  such
standalone  license.  Such payment shall be made to APB within fifteen (15) days
after  the  last  day of each  calendar  quarter  in  which a  software  license
agreement has been executed for such standalone  license,  provided that APB has
registered  such  End  User  as a  prospect  in  accordance  with  the  criteria
established by the Parties pursuant to Section 5.8(b).

     6.3 BIOTECH MARKET.

         (a) For every license to the Data Analysis Products granted by APB, its
Subsidiaries  and  Resellers to End Users in the Biotech  Market,  APB shall pay
InforMax eighty percent (80%) of the net license fees and  Maintenance  Fees (to
be paid at the  time of the  license  grant)  owed by each End User for the Data
Analysis Products pursuant to such transaction.

              EXECUTION COPY - DATA ANALYSIS PRODUCTS DEVELOPMENT
                      AND DISTRIBUTION AGREEMENT - PAGE 10

<PAGE>

         (b) In the event that an End User in the Biotech  Market decides not to
license the Data Analysis Products,  but does license the InforMax Software on a
standalone basis directly from InforMax, then InforMax shall pay APB ten percent
(10%) of the net license fee paid to InforMax for such standalone license.  Such
payment shall be made to APB within fifteen (15) days after the last day of each
calendar  quarter in which a software  license  agreement  has been executed for
such  standalone  license,  provided that APB has registered  such End User as a
prospect in accordance with the criteria  established by the Parties pursuant to
Section 5.8(b).

     6.4 ANNUAL MAINTENANCE PAYMENTS. APB shall also be required to pay InforMax
all  recurring  annual  Maintenance  Fees paid by each End User  pursuant to the
percentage  amounts set forth in Sections 6.2 and 6.3 above. Such payments shall
be paid within fifteen (15) days after the last day of each calendar  quarter in
which such annual Maintenance Fees were paid by the End User.

     6.5 MINIMUM  PAYMENT  AMOUNTS.  The royalty  base (i.e.  the base amount on
which  license fees and  Maintenance  Fees will be paid) used for  computing the
license  fees and  Maintenance  Fees to be paid by APB to  InforMax  pursuant to
Sections  6.2 (a) and 6.3 (a) shall in no event be less than eighty five percent
(85%) of the then-current  suggested list price for the Data Analysis  Products,
except that APB shall be entitled  during the term of this  Agreement to apply a
royalty base of less than eighty five percent  (85%) in up to three (3) separate
transactions  in which APB has granted  discounts  greater than fifteen  percent
(15%) to the End User. In connection  with any of the  aforementioned  three (3)
exempt  transactions,  the  applicable  royalty  base shall be the  then-current
suggested list price minus the discount granted by APB, provided  however,  that
in the event of a transaction  in which the Data  Analysis  Products are bundled
with APB  products  or  services  other  than the Data  Analysis  Products,  the
discount to be deducted can not be greater than any discount  granted to the End
User with respect to the bundled APB products or services.

     6.6 TAXES.  APB agrees to bear and be  responsible  for the  payment of all
federal, state, local and foreign taxes, levies and assessments that arise under
this Agreement, excluding any taxes based on InforMax's net income.

     6.7 REPORTS.  Within sixty (60) days  following  the close of each calendar
quarter,  APB shall provide  InforMax with a written report showing the revenues
attributable  to the Data  Analysis  Products for such quarter and the amount of
and  Maintenance  Fees payable to InforMax  with respect  thereto.  Such reports
shall  also  specify  the  amount  of  revenues  generated  by each of APB,  its
Subsidiaries and its Resellers related to the Data Analysis  Products.  If there
are no revenues in a calendar quarter, the report shall so state.

              EXECUTION COPY - DATA ANALYSIS PRODUCTS DEVELOPMENT
                      AND DISTRIBUTION AGREEMENT - PAGE 11

<PAGE>

     6.8 EXAMINATIONS AND AUDITS.

         (a) AUDIT BY INFORMAX.  Not more than once per calendar year,  upon the
written  request  of  InforMax  and,  except as  otherwise  provided  below,  at
InforMax's  expense,  APB shall  allow the books  and  records  related  to Data
Analysis  Products of APB and its  Subsidiaries  to be examined and audited by a
reputable accounting firm selected by InforMax that is reasonably  acceptable to
APB for the purpose of determining APB's compliance with its payment obligations
pursuant to this Section 6;  provided,  however,  that APB receives at a minimum
two (2) weeks prior written notice, the audit takes place during normal business
hours and the auditors agree to keep such books and records  confidential except
for reasonable disclosures to InforMax in describing any noncompliance of APB or
as needed by InforMax in enforcing  this Agreement in the event of such reported
noncompliance.  In the event that any such  examination or audit shall determine
that  payments  actually paid during any period were less than 95% of the amount
properly  payable,  APB shall pay the reasonable  expenses  actually incurred by
InforMax in  connection  with such audit,  in addition to paying all  previously
unpaid payments.  InforMax and its representatives  shall not use or disclose to
any third  parties the contents of such books and records  except as  reasonably
necessary if there is a breach of this Agreement.

         (b)  AUDIT BY APB.  Not more  than  once per  calendar  year,  upon the
written request of APB and at APB's expense,  InforMax shall allow the books and
records of InforMax related to payment  obligations set forth in Sections 6.2(c)
and 6.3(c) to be examined  and audited by a  reputable  accounting  firm that is
reasonably acceptable to InforMax;  provided, however, that InforMax receives at
a minimum  two (2) weeks prior  written  notice,  the audit  takes place  during
normal  business  hours and the  auditors  agree to keep such books and  records
confidential  except  for  reasonable  disclosures  to  APB  in  describing  any
noncompliance of InforMax or as needed by APB in enforcing this Agreement in the
event of such reported noncompliance.

     6.9  LICENSES  TO  UNNAMED  END  USERS.  In  the  event  that  APB  or  its
Subsidiaries  or  Resellers  desire to license the Data  Analysis  Products to a
prospective  End User that is not in the Life  Sciences  Market  or the  Biotech
Market,  then the Parties shall mutually agree upon the terms and conditions for
such desired license on a case-by-case basis.

SECTION 7 - INDEMNIFICATION

     (a)   INTELLECTUAL   PROPERTY  RIGHTS   INDEMNIFICATION.   Subject  to  the
limitations set forth below, InforMax shall indemnify,  defend and hold harmless
APB, its Subsidiaries  and the End Users from and against all actions,  damages,
liabilities,  costs  and  expenses,  including  reasonable  attorney's  fees and
expenses,  arising from any third party claim that use of the InforMax Software,
the Marks  and/or  the Data  Analysis  Products,  and any  maintenance  services
related  thereto,  infringes  any  existing  United  States  patent,  copyright,
trademark or trade secret.

     (b)  INTELLECTUAL  PROPERTY  RIGHTS  EXCLUSIONS.  InforMax  shall  have  no
indemnification  obligation  under  Section  7(a)  or  other  liability  for any
infringement  claim  resulting  or alleged to result  from:  (1) use of the Data
Analysis  Products  or  InforMax  Software in  combination  with any  equipment,
software or data not  approved  for use by InforMax to the extent such  combined
use is  directly  the cause of the  infringement;  (2) use of the Data  Analysis
Products or InforMax Software in any manner for which the Data Analysis Products
or InforMax

              EXECUTION COPY - DATA ANALYSIS PRODUCTS DEVELOPMENT
                      AND DISTRIBUTION AGREEMENT - PAGE 12

<PAGE>

Software was not designed;  (3)  modification  of the InforMax  Software or Data
Analysis  Products by any party other than InforMax or InforMax's  agent; or (4)
the  indemnified  party's  continued use of the allegedly  infringing item after
being notified  thereof or after being informed and provided with  modifications
that would have avoided the alleged infringement.

         (c)  INFRINGEMENT  REMEDIES.  In the  event  of an  infringement  claim
relating to the Data  Analysis  Products or InforMax  Software as  described  in
Section 7(a) above arises,  or if InforMax  reasonably  believes that a claim is
likely to be made, APB must discontinue use, distribution, marketing and copying
of the infringing  portion of the Data Analysis  Products and InforMax  Software
when InforMax so requests in writing, provided that InforMax has made reasonable
efforts to: (i) modify the InforMax  Software or Data Analysis  Products so that
it becomes non-infringing but functionally equivalent; (ii) replace the InforMax
Software or Data Analysis  Products with  material  that is  non-infringing  but
functionally equivalent;  or (iii) obtain for the indemnified party the right to
use the InforMax Software or Data Analysis Products.

         (d) PERSONAL  INJURY AND PROPERTY  DAMAGE  INDEMNITY.  Each Party shall
indemnify,  defend and hold harmless the other Party and its  subsidiaries  from
and against all actions,  damages,  liabilities,  costs and expenses,  including
reasonable attorneys' fees and expenses,  arising from any third party claim for
bodily  injury or damage to real or  tangible  personal  property  to the extent
caused by the gross negligence or willful  misconduct of the indemnifying  party
or its employees or agents.

         (e) APB  INDEMNITY.  APB  shall  indemnify,  defend  and hold  harmless
InforMax  and  its   subsidiaries   from  and  against  all  actions,   damages,
liabilities,  costs  and  expenses,  including  reasonable  attorney's  fees and
expenses,  arising  from any third  party  claim  related  to APB's  and/or  its
Subsidiaries'  or  Resellers'  distribution,  marketing  or use of the  InforMax
Software and Data Analysis Products, other than claims described in 7(a) above.

         (f)  INFORMAX  INDEMNITY  InforMax  shall  indemnify,  defend  and hold
harmless  APB and its  Subsidiaries  from  and  against  all  actions,  damages,
liabilities,  costs  and  expenses,  including  reasonable  attorney's  fees and
expenses,  arising from any third party claim related to  InforMax's  and/or its
subsidiaries'  Maintenance in respect of the InforMax Software and Data Analysis
Products, other than claims described in 7(a) above.

         (g) INDEMNIFICATION  PROCEDURES.  The obligations to indemnify,  defend
and hold  harmless  set  forth  above in  Sections  7(a) and 7(e) will not apply
unless the indemnified party (i) promptly notifies the indemnifying party of any
matters in respect of which the indemnity may apply and of which the indemnified
party has  knowledge;  (ii) gives the  indemnifying  party full  opportunity  to
control the response  thereto and the defense  thereof,  including any agreement
relating to the settlement  thereof,  provided that the indemnifying party shall
not settle any such claim or action  without  the prior  written  consent of the
indemnified  party (which shall not be  unreasonably  withheld or delayed);  and
(iii) cooperates with the indemnifying  party, at the indemnifying  party's cost
and expense,  in the defense or settlement  thereof.  The indemnified  party may
participate,  at its  own  expense,  in  such  defense  and  in  any  settlement
discussions  directly  or  through  counsel  of  its  choice  on  a  monitoring,
non-controlling basis.

              EXECUTION COPY - DATA ANALYSIS PRODUCTS DEVELOPMENT
                      AND DISTRIBUTION AGREEMENT - PAGE 13

<PAGE>

SECTION 8 - WARRANTIES

     8.1 NO CONFLICT.  Each Party  represents and warrants that it has the right
and  power  to enter  into  this  Agreement  and that  this  Agreement  does not
materially conflict with any existing obligation of the Party.

     8.2 INFORMAX'S  REPRESENTATIONS  AND  WARRANTIES.  InforMax  represents and
warrants the following:

         (a) At the time of Acceptance,  the Data Analysis Products will be free
of any viruses and malicious or harmful programs or instructions.

         (b) InforMax shall not include in its design or programming of the Data
Analysis  Products  any  computer  time-bomb,  kill  switch,  trap-door or other
similar methods of disabling the Data Analysis Products either by date and time,
remote  access,  failure to  install  the proper  code to  inactivate,  or other
method,  excluding  any  feature  or  function  of the  Data  Analysis  Products
identified in the Documentation or otherwise disclosed or known to APB.

         (c)  InforMax is the sole owner of the  InforMax  Software,  and to the
extent the  InforMax  Software  contains any third party  products  InforMax has
valid licenses to grant the rights set forth herein,  and the InforMax  Software
is free and clear of all  claims,  liens  and  demands  of any  other  person or
entity.  To the  knowledge  of  InforMax,  the  InforMax  Software  and the Data
Analysis  Products do not infringe on the  intellectual  property  rights of any
third party.

         (d)  InforMax has the full power,  authority  and right to grant to APB
all of the rights  granted  under by this  Agreement  and the  granting  of such
rights does not violate the rights of any other person or entity.

         (e) The services  performed by InforMax hereunder shall be performed in
a professional and workmanlike manner in accordance with industry standards.

         (f) The Data Analysis Products will materially  conform to and function
in all material respects in accordance with the Specifications.

     8.3 APB'S  REPRESENTATIONS  AND  WARRANTIES.  APB  hereby  represents   and
warrants the following:

         (a) APB shall discharge its obligations hereunder in a professional and
workmanlike manner in accordance with industry standards.

         (b) APB shall not grant to its  Subsidiaries  or  Resellers  any rights
greater than those that InforMax has granted to APB hereunder.

              EXECUTION COPY - DATA ANALYSIS PRODUCTS DEVELOPMENT
                      AND DISTRIBUTION AGREEMENT - PAGE 14

<PAGE>

     8.4  REMEDIES.  In the event that  either  Party  fails to comply  with its
respective  obligations  specified in Sections 8.2(e) and 8.3(a)-(b),  the other
Party,  without  limiting any other remedy  available to it under law or equity,
may at its option,  require the breaching Party to use  commercially  reasonable
efforts to cure such breach.

     8.5 DISCLAIMERS. EXCEPT AS PROVIDED HEREIN, EACH PARTY DIS-CLAIMS ALL OTHER
WARRANTIES,  WHETHER  EXPRESS OR,  IMPLIED,  INCLUDING  WITHOUT  LIMITATION  ALL
WARRANTIES OF  MERCHANT-ABILITY  AND FITNESS FOR A PARTICULAR PURPOSE OR ARISING
FROM A COURSE OF  DEALING,  USAGE,  TRADE OR  PRACTICE.  INFORMAX  SPECIFI-CALLY
DISCLAIMS THAT THE INFORMAX SOFTWARE AND THE DATA ANALYSIS PRODUCTS WILL OPERATE
UNINTERRUPTED OR ERROR FREE.

SECTION 9 - LIMITATION OF LIABILITY

     9.1  LIMITATION ON LIABILITY.  IN NO EVENT SHALL EITHER  PARTY'S  AGGREGATE
LIABILITY  TO THE OTHER PARTY AND ITS  SUBSIDIARIES  ARISING FROM OR RELATING TO
THIS AGREEMENT,  REGARDLESS OF THE FORM OF ACTION WHETHER IN CONTRACT, WARRANTY,
TORT, OR OTHERWISE,  EXCEED THE TOTAL AMOUNT PAID BY APB TO INFORMAX  UNDER THIS
AGREEMENT  DURING THE  THIRTY-SIX  (36) MONTH PERIOD  PRECEDING THE DATE OF SUCH
CAUSE OF ACTION. IN NO EVENT SHALL EITHER PARTY BE LIABLE FOR ANY CONSEQUENTIAL,
SPECIAL,  INDIRECT,  INCIDENTAL  OR  PUNITIVE  DAMAGES,  OR ANY  LOSS  OF  DATA,
SOFTWARE,  OR PROFITS, EVEN IF SUCH PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF
THEREOF. THE PARTIES HAVE AGREED THAT THE LIMITATIONS  SPECIFIED IN THIS SECTION
9.1  WILL  SURVIVE  AND  APPLY  EVEN IF ANY  LIMITED  REMEDY  SPECIFIED  IN THIS
AGREEMENT  IS  FOUND TO HAVE  FAILED  ITS  ESSENTIAL  PURPOSE.  THIS  AGREEMENT,
INCLUDING ITS DISCLAIMERS  AND  LIMITATIONS ON LIABILITY,  REPRESENTS A MUTUALLY
AGREED UPON ALLOCATION OF RISK BY THE PARTIES.

SECTION 10 - CONFIDENTIALITY

    10.1 CONFIDENTIALITY.

         (a) DEFINITION.  The term "Confidential Information" shall mean any and
all information or proprietary materials (in every form and media) not generally
known by the  public  and  which  has  been or is  hereafter  disclosed  or made
available  by either  Party (the  "Disclosing  Party")  to the other  Party (the
"Receiving  Party")  in  connection  with the  efforts  contemplated  hereunder,
including,   without  limitation  (i)  all  trade  secrets,   (ii)  existing  or
contemplated products, services, designs,  technology,  source code, algorithms,
processes, technical data, engineering,  techniques,  methodologies and concepts
and any information related thereto,  and (iii) information relating to business
plans,  sales,  financial and accounting data, or marketing methods and customer
lists or requirements.

              EXECUTION COPY - DATA ANALYSIS PRODUCTS DEVELOPMENT
                      AND DISTRIBUTION AGREEMENT - PAGE 15

<PAGE>

         (b)  CONFIDENTIAL  INFORMATION.  Both Parties  acknowledge  that either
Party may  receive  Confidential  Information  from the other  Party  under this
Agreement,  including  information  designated  as  confidential  at the time of
disclosure,  which the  Receiving  Party  could have  reasonably  determined  is
confidential,  or is  marked as  "confidential"  or  summarized  in  writing  as
Confidential  Information  within  a  reasonable  time  after  disclosure.   The
Receiving Party shall disclose the Disclosing Party's  Confidential  Information
only to  persons  within  the  Receiving  Party  having  the  need  to know  the
information for the purpose of this  Agreement.  The Receiving Party shall treat
Confidential  Information as it does its own valuable and sensitive  information
of a similar nature, and, in any event, with not less than reasonable care. Upon
the Disclosing  Party's  written  request,  the Receiving  Party shall return or
certify the destruction of all Confidential Information.

         (c)  EXCEPTIONS.  The obligations of either Party under Section 10.1(b)
will not apply to information  that the Receiving  Party can demonstrate (i) was
in its  possession  at the time of  disclosure  and  without  restriction  as to
confidentiality,  (ii) at the time of disclosure  is generally  available to the
public or after disclosure becomes generally  available to the public through no
breach of agreement or other wrongful act by the Receiving Party, (iii) has been
received from a third party without restriction on disclosure and without breach
of agreement or other wrongful act by the Receiving Party, (iv) is independently
developed by the Receiving Party without regard to the Confidential  Information
of the other  Party,  or (v) is  required to be  disclosed  by law or order of a
court of competent  jurisdiction  or  regulatory  authority,  provided  that the
Receiving Party shall furnish prompt written notice of such required  disclosure
and reasonably  cooperate with the Disclosing  Party, at the Disclosing  Party's
cost  and  expense,  in any  effort  made  by the  Disclosing  Party  to  seek a
protective   order  or  other   appropriate   protection  of  its   Confidential
Information.

         (d) INJUNCTIVE RELIEF.  Failure on the part of either Party to abide by
this Section 10 will cause the other Party  irreparable  harm for which damages,
although  available,  will not be an adequate  remedy at law.  Accordingly,  the
Party  that will be harmed  shall  have the  right to  obtain an  injunction  to
prevent any further  violations  of this Section 10 and may recover  court costs
and reasonable  attorney fees incurred by such Party in the  enforcement of this
Section  10 in the  event  that  such  Party is  successful  in  obtaining  such
injunction.

SECTION 11 - SPECIAL PROVISIONS

     11.1 TRADEMARKS. Nothing in this Agreement grants to either Party the right
to use any trademark or service mark or  commercial  symbol or logo of the other
Party except as expressly provided in Section 3.1.

     11.2  COMPLIANCE  WITH LAWS.  Both Parties shall comply with all applicable
laws, rules and regulations concerning this Agreement.  APB shall be responsible
for obtaining any approval, license or authorization by, and any registration or
filing  with,  any  government  or  agency  needed  for  this  Agreement  or the
world-wide  use and  distribution  contemplated  by this  Agreement.  Upon APB's
request and at APB's  expense,  InforMax will provide  reasonable  assistance to
assist APB in  obtaining  any  approval,  license or  authorization  by, and any
registration  or filing with, any government or agency needed for this Agreement
or the world-wide use and distribution contemplated by this Agreement.

              EXECUTION COPY - DATA ANALYSIS PRODUCTS DEVELOPMENT
                      AND DISTRIBUTION AGREEMENT - PAGE 16

<PAGE>

     11.3  SOURCE  CODE  ESCROW.  APB  shall  be  entitled  to  be  named  as  a
beneficiary  under  InforMax's  standard  source code escrow  agreement  for the
InforMax Software, the form of which is attached hereto as Exhibit D.

SECTION 12 - TERM AND TERMINATION

     12.1 TERM OF AGREEMENT. The term of the this Agreement shall be twenty (20)
years  unless  terminated  by mutual  written  agreement  of the  Parties  or as
otherwise provided in this Agreement.

     12.2 BREACH.  Except as otherwise  set forth  herein,  if APB breaches this
Agreement in any material  respect and fails to cure such breach  within  thirty
(30) days of written  notice of such breach,  then InforMax may  terminate  this
Agreement.  This right to terminate this Agreement  shall be in addition to, and
shall in no way limit, any other remedies,  damages and relief to which InforMax
may be entitled. Except as otherwise set forth herein, if InforMax breaches this
Agreement in any material  respect and fails to cure such breach  within  thirty
(30)  days of  written  notice  of such  breach,  then  APB may  terminate  this
Agreement.  This right to terminate this Agreement  shall be in addition to, and
shall in no way limit,  any other remedies,  damages and relief to which APB may
be entitled.

     12.3 EFFECT OF  TERMINATION/EXPIRATION.  Upon  expiration or termination of
this  Agreement,  (i) APB shall have no further rights under this Agreement with
respect to InforMax  Software and shall cease all use,  copying and distribution
thereof;  (ii) InforMax shall  immediately  deliver to APB a copy of the Jointly
Developed Code (whether  complete or not);  (iii) APB and its  Subsidiaries  may
continue to provide support to these End Users; and (iv) to the extent necessary
and permitted by the source code escrow agreement  attached hereto as Exhibit D,
APB shall be entitled to a copy of the portions of the InforMax  Software source
code necessary for APB to continue to provide support to End Users. Any End User
License  Agreements  granted to End Users prior to  termination or expiration of
this Agreement may continue in effect and unaffected by such termination.

SECTION 13 - GENERAL PROVISIONS

     13.1  GOVERNING  LAW. This  Agreement  shall be governed by and enforced in
accordance with the laws of the state of Delaware.

     13.2  ENTIRE  AGREEMENT.  This  Agreement  (including  its  Exhibits):  (i)
represents  the entire  agreement  between the  Parties  relating to the subject
matter of this Agreement, (ii) supersedes all prior agreements,  understandings,
letters,  representations  and warranties relating to the subject matter of this
Agreement,  whether  written or oral, and (iii) may only be amended by a writing
signed by duly authorized representatives of both Parties.

     13.3 ASSIGNMENT. In the absence of the other Party's prior written consent,
neither  Party  shall  have the right or the power to  assign or  transfer  this
Agreement.  Notwithstanding the

              EXECUTION COPY - DATA ANALYSIS PRODUCTS DEVELOPMENT
                      AND DISTRIBUTION AGREEMENT - PAGE 17

<PAGE>

foregoing:  (i) APB may, without  InforMax's prior written consent,  assign this
Agreement to its Subsidiary, provided that APB first guarantees to InforMax such
Subsidiary's compliance with this Agreement; and (ii) either Party, may, without
the other Party's prior written consent,  assign this Agreement to a third party
in the event of a sale of all or substantially all of its assets or in the event
of a merger or  consolidation  in which the assigning Party is not the surviving
entity  or there is a change  of  control  of such  assigning  Party,  provided,
however,  that APB shall have the right to terminate this Agreement in the event
of any such  assignment  provided  that APB has not yet  accepted the first Data
Analysis Product.

     13.4  NOTICES.  All notices and consents  permitted or required  under this
Agreement  must be in writing and shall be delivered in person,  by first class,
priority or express  mail,  by  registered  or certified  mail, or by commercial
courier (e.g.,  Federal Express or U.P.S.) to the other Party at the address set
forth at the beginning of this  Agreement or such  substitute  address as either
Party may specify by written  notice for itself.  All notices shall be effective
upon receipt.

     13.5 HEADINGS.  Headings used herein are for convenience only and shall not
be used to broaden or limit this Agreement.

     13.6  SEVERABILITY.  If any  provision  in this  Agreement  is  invalid  or
unenforceable,  such  provision  shall be construed,  limited,  or if necessary,
severed   to  the   extent   necessary   to   eliminate   such   invalidity   or
unenforceability,  and all other  provisions of this  Agreement  shall remain in
effect.

     13.7 DISPUTE  RESOLUTION.  In the event of any dispute  between the Parties
relating  to this  Agreement  or its  subject  matter,  they shall first seek to
amicably resolve or settle the dispute in good faith by mutual agreement. If the
Parties have not reached a resolution or settlement  within fifteen (15) days of
the  provision of notice by one Party to the other Party of its intent to invoke
its rights  under this  Section  13.7,  then either Party may after such fifteen
(15) day period submit the dispute to arbitration, and if so submitted, shall be
finally  settled by  arbitration  conducted in  accordance  with the  commercial
arbitration rules of the American Arbitration  Association or its successor.  In
the event of any conflict between such rules and this Section 13.7, this Section
13.7 shall govern.  The Parties  shall attempt to mutually  agree upon a neutral
arbitrator.  If the Parties cannot reach such agreement,  they shall request the
American  Arbitration  Association  or its  successor  to  designate  a  neutral
arbitrator. Such arbitrator shall not render a decision that is in conflict with
the terms and  conditions  agreed  upon by the  Parties in this  Agreement.  The
arbitration  shall be conducted in New Jersey if the  arbitration is demanded by
or initiated  by InforMax and shall be conducted in Maryland if the  arbitration
is  demanded  by or  initiated  by  APB.  The  institution  of  any  arbitration
proceeding  hereunder  shall not  relieve  any Party of its  obligation  to make
undisputed  payments under this Agreement.  The decision by the arbitrator shall
be binding  and  conclusive  upon the  Parties,  their  successors,  assigns and
trustees and they shall comply with such decision in good faith,  and each Party
hereby submits itself to the jurisdiction of the State and Federal courts of the
place where the  arbitration  is held, but only for the entry of judgment or for
the enforcement of the decision of the arbitrator  hereunder.  Judgment upon the
award may be entered in any court having jurisdiction.  Notwithstanding anything
herein to the contrary, neither Party has any obligation to arbitrate any claims
relating  to  the   infringement   or  violation  of  its  copyrights  or  other
intellectual  property or the unlicensed use, disclosure or transfer of any Data
Analysis  Products.  Such Party may assert such claims in any court of competent
jurisdiction at any time.

              EXECUTION COPY - DATA ANALYSIS PRODUCTS DEVELOPMENT
                      AND DISTRIBUTION AGREEMENT - PAGE 18

<PAGE>

     13.8 RELATIONSHIP.  Neither Party is the partner, joint venturer,  agent or
representative  of the other  Party.  Each Party is an  independent  contractor.
There is no employment  relationship between the Parties.  Neither Party has the
authority to make any  representations or warranties or incur any obligations or
liabilities  on  behalf  of the  other  Party.  Neither  Party  shall  make  any
representation to a third party inconsistent with this Section 13.8.

     13.9  CONSTRUCTION.  This Agreement  represents the wording selected by the
Parties to define their agreement and no rule of strict construction shall apply
against  either Party.  Whenever the context  reasonably  permits,  the singular
shall include the plural,  the plural shall include the singular,  and the whole
shall include any part thereof.

     13.10  WAIVER.  Any waiver of, or promise not to  enforce,  any right under
this Agreement shall not be enforceable  unless evidenced by a writing signed by
the Party making said waiver or promise.

     13.11 EMPLOYEE  HIRING.  Neither Party will hire a current  employee of the
other Party who performs in any capacity under this Agreement  without the prior
written consent of the other Party. Notwithstanding the foregoing, neither Party
shall be  restricted  from  hiring an  employee  of the other  Party by means of
general advertisement.

     13.12  SUCCESSORS.  This  Agreement  shall be binding upon and inure to the
benefit of the Parties and their respective permitted successors and assigns.

     13.13 SURVIVAL.  The following  sections shall survive  termination of this
Agreement and remain in effect: 2.5, 6, 8.5, 9, 10, 11, 12 and 13.

     13.14 EXECUTION.  This Agreement may be executed in any number of duplicate
counterparts,  each of which shall be deemed an original, but all of which taken
together  shall  constitute  one and the same  instrument.  Each of the  persons
signing below  represent that they are duly authorized to execute this Agreement
for and on behalf of the Party for whom they are signing.

                            [SIGNATURE PAGE FOLLOWS]

              EXECUTION COPY - DATA ANALYSIS PRODUCTS DEVELOPMENT
                      AND DISTRIBUTION AGREEMENT - PAGE 19

<PAGE>

         IN WITNESS WHEREOF, the authorized  representatives of the parties have
executed this Data Analysis Products  Development and Distribution  Agreement as
of the date set forth above.

AMERSHAM PHARMACIA BIOTECH, INC.:           INFORMAX, INC.:

By: /s/ Peter B. Coggins                    By: /s/ Alexander Titomirov
   --------------------------------            ---------------------------------

Name:   Peter B. Coggins                    Name: Alexander Titomirov
     ------------------------------              -------------------------------

Title: V.P. Drug Discovery                  Title: President/CEO
      -----------------------------               ------------------------------

              EXECUTION COPY - DATA ANALYSIS PRODUCTS DEVELOPMENT
                      AND DISTRIBUTION AGREEMENT - PAGE 20

<PAGE>

                                    EXHIBIT A

A.   DEVELOPMENT PLATFORM DOCUMENTATION:

     I.    A written description of the tools used for designing the integration
           capability supported in the GenoMax system.

     II.   A  written  description  of the  middleware  application  programming
           interfaces  (APIs) that exist for  integrating  tools as is presently
           done with GenoMax. This documentation shall include an enumeration of
           all  internal  development  APIs and object  definitions,  along with
           definitions  of how these APIs are used along with  examples  of use.
           The documentation  shall include references to : internal object data
           models;  APIs  for  reading  in and  writing  out  objects;  APIs for
           updating  and  modifying;   APIs  and  instructions  for  adding  new
           databases/data   models  to  GenoMax;   APIs  and  configuration  for
           integrating new GUI based JAVA tools into GenoMax;  API  instructions
           for  tightly  integrating  external  tools so that  they  can  update
           database structures; APIs for all "hook" functionality of all current
           and near future GenoMax modules. All additional collateral documents,
           if any, necessary or helpful in compiling the above.

B.   Data Analysis Products Technical Specifications:  [To be provided]

C.   Acceptance Testing Criteria:  [To be provided]

D.   Formal Development Plan:  [To be provided]

              EXECUTION COPY - DATA ANALYSIS PRODUCTS DEVELOPMENT
                      AND DISTRIBUTION AGREEMENT - PAGE 21

<PAGE>

                                    EXHIBIT B

A.   InforMax Software:

     (i)   Vector NTI

     (ii)  GenoMax

              EXECUTION COPY - DATA ANALYSIS PRODUCTS DEVELOPMENT
                      AND DISTRIBUTION AGREEMENT - PAGE 22

<PAGE>

                                    EXHIBIT C

A.   The following trademarks,  service  marks and logos are licensed for use to
     APB pursuant to the terms of the Agreement:

     (i)  The following are registered trademarks of InforMax:

               ALIGNX

               BIOPLOT

               INFORMAX (stylized with logo)

               VECTOR NTI

     (ii) InforMax is pursuing trademark registration of the following:

               CONTIGEXPRESS

               INFORMAX (word only)

               GENOMAX

               HIGH-THROUGHPUT RESEARCH

               HTR

               HTR PARTNERS PROGRAM

               PROTEOMAX

               RESEARCHLOGIC

               RESEARCHLOGIC EXTENSION

               SOFTWARE SOLUTION for BIO-MEDICINE

               SSBM

              EXECUTION COPY - DATA ANALYSIS PRODUCTS DEVELOPMENT
                      AND DISTRIBUTION AGREEMENT - PAGE 23

<PAGE>

                                    EXHIBIT D

A.  InforMax standard source code escrow agreement: (see attached)

              EXECUTION COPY - DATA ANALYSIS PRODUCTS DEVELOPMENT
                      AND DISTRIBUTION AGREEMENT - PAGE 24

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00015-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00015-of-00352.parquet"}]]